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Abstract
Background: Information on the biology of metastasis development in salivary gland tumors is
scarce. Since angiogenesis seems associated with this phenomenon in other tumors, we sought to
compare salivary gland tumors with diverse metastatic behavior in order to improve the knowledge
and management of these lesions.
Methods: Samples from the most important salivary gland tumors were segregated according to
its metastatic behavior and submitted to routine immunohistochemistry to identify vessels positive
for CD105 expression. Frequency of positive cases and intratumoral microvessel density (IMD)
was compared among the group of lesions.
Results:  CD105 positive vessels were absent in normal salivary gland tissue, were rare in
pleomorphic adenomas and adenoid cystic carcinomas (ACC), more common in polymorphous
low-grade adenocarcinomas and highest in mucoepidermoid carcinomas. Only ACC with such
feature were metastatic. IMD was higher in malignant rather than benign tumors.
Conclusion:  Immunostaining of CD105 in salivary gland tumors implies participation of
angiogenesis in the development of malignant lesions, as well as some role for myoepithelial cells
in the control of new vessel formation. In addition, suggest that ACC with positive CD105 vessels
are at higher risk for metastasis.
Background
Malignant salivary gland tumors constitute a major chal-
lenge in head and neck oncology because of its frequency,
varied histological typing, difficult surgical approach, and
poor response to other therapies. It is further complicated
by the absence of clear parameters to preview biological
behavior, in particular to predict development of metasta-
sis. In this sense, there is few information regarding path-
ways implicated in tumor dissemination of salivary gland
cancer.
Tumor growth is limited by the balance between neoplas-
tic demand for oxygen and nutrients and diffusion from
preexisting surrounding vascularization, and therefore
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formation of new blood vessels is an essential step in pro-
gression of cancer [1]. In general, this process is named
angiogenesis, requires release of activating mediators as
well as suppression of inhibitory mechanisms, and may
evolve through several mechanisms, such as sprouting,
intussusception, recruitment, cooption, and mimicry [2].
Both angiogenesis and neoplastic invasion and metastasis
are associated with increasing vascular surface, remode-
ling of extracellular matrix, and secretion of growth factors
[3].
In situ quantification of microvessel density by immuno-
histochemistry is a usual form to assess angiogenesis for
different types of neoplasia. However, inconsistencies and
contradictions have been pointed out, in particular
because of the use of endothelial markers which are una-
ble to distinguish true angiogenic endothelial activity [4-
6]. CD105, also known as endoglin, is a receptor for TGFβ
signaling, and play an important role in angiogenesis and
fibrogenesis [7,8]. It is essential for endothelial cell prolif-
eration, thus promoting the activation phase of angiogen-
esis [9]. More important, CD105 expression is a
prominent feature of newly formed tumor vessels but
minimally expressed in quiescent preexisting ones [7,10].
It is also a prognostic marker for squamous cell carcinoma
of the head and neck [11,12].
Finally, there is few information translating the relation-
ship between angiogenesis and dissemination of salivary
gland tumors to clinical-driven parameters. In this sense,
this work was conducted to investigate whether lesions
with diverse clinical course also differ in their neovascular
content.
Methods
Tissue samples and patients characteristics
The use of archived human tissues, as well as the entire
research protocol, was reviewed and approved by the
Institutional Review Board of the Brazilian National Insti-
tute of Cancer (reference 42/04). Histological samples
and follow up data were obtained from the Division of
Pathology and from the Head and Neck Service, respec-
tively, of the Brazilian National Cancer Institute, Rio de
Janeiro, Brazil. It was initially gathered cases of epithelial
salivary gland neoplasms that were surgically resected as
the first therapeutic intervention in the period between
1998 and 2004. Further selection of those patients with
specific histological types of interest, with the most char-
acteristic features for each type as reviewed by an expert
pathologist (A. M. L.) [13], and minimum follow-up of
five years or up to identification of metastasis, resulted in
a final series of 139 cases, comprising pleomorphic ade-
nomas (PA), adenoid cystic carcinomas (ACC), polymor-
phous low-grade adenocarcinomas (PLGA), and
mucoepidermoid carcinomas (MEC). Non-neoplastic sal-
ivary gland tissue at the periphery of the samples was also
screened.
Immunohistochemistry
CD105 expression was assessed in 3 μm thick tissue sec-
tions cut from formalin-fixed, paraffin-embedded speci-
mens. Antigen retrieval was performed in deparaffinized,
rehydrated samples with 1 mM EDTA (pH 8.0) in micro-
wave environment (3 × 5 min). After washing in distilled
water and TRIS-HCl buffer (0.5 M, pH 7.4), the slides were
incubated in 3% hydrogen peroxide (20 min), once again
washed, and incubated with endogenous avidin and
biotin-blocking solution (purchased from Dako, Carpin-
teria, CA, USA) for 20 minutes each. Slides were rinsed
with water and buffer, and then primary mouse antibody
(clone SN6h, purchased from Dako), titrated at 1:100,
was applied for 19 hours at 4°C. Amplification of the
reaction was performed with secondary biotynilated anti-
mouse antibody (Vector Labs, Burlingame, CA) and
streptavidin-biotin-peroxidase (Dako) for 30 minutes
each. After extensive washing, reaction was revealed with
3,3'-diaminobenzidine hydrochloride (Sigma, St. Louis,
MI) and 0.02% peroxide hydrogen, followed by counter-
staining with Mayer's hematoxylin. Omission of the pri-
mary antibody was employed as negative control, while
large B-cell lymphoma and tonsil tissue were used as pos-
itive controls.
Intratumoral microvessel density (IMD) was quantitated
according to a recent consensus statement [14]. Briefly, in
an optical microscope (E400, Nikon Instruments,
Melville, NY) hot-spot areas for CD105 expression in dis-
crete blood vessels were initially identified by scanning
the entire tumor at low power (× 50 and × 125). The
number of CD105 highlighted vessels in 10 of these areas
was then counted in high power magnification (× 500).
Statistics
Possible associations between metastatic behavior and
positivity for CD105 were tested by chi-square or Fisher's
exact tests. Non-parametric tests were employed to evalu-
ate differences in IMD between benign and malignant
tumors, primary non-metastasizing and metastasizing
malignant lesions (Mann-Whitney test), and among dif-
ferent histological types of neoplasms (Kruskal-Wallis
with Dunn's post hoc test).
Results
Most of the patients were women (60.4%), ranging from
6 to 86 years of age at the time of admission, as shown in
Table 1. For malignant tumors, median follow-up time
was 44.1 months, metastatic dissemination was observed
in 16 cases (14.7% of these lesions), and three patients
(two ACC and one MEC) had two organs affected (Figure
1).BMC Cancer 2009, 9:391 http://www.biomedcentral.com/1471-2407/9/391
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CD105 positive vessels were absent in normal salivary
gland tissue in the vicinity of the tumors (present in 83
samples). In tumors, staining was observed as cytoplasmic
brown deposits in endothelial cells of capillary vessels.
Frequency of CD105 positivity was significantly higher in
malignant (42.2%) rather than pleomorphic adenomas
(with 10.0%; p = 0.001, Fisher's exact test), but it was very
similar between non-metastasizing and metastasizing pri-
mary malignant tumors (Figure 2A). Among malignant
neoplasms, there was graded frequency of positivity for
CD105, with MEC being the highest (85.0%), followed by
PLGA (42.1%), and ACC (with 8.0%; p < 0.0001, chi-
square test, Figure 2B). IMD was also elevated in malig-
nant neoplasms compared to benign tumors (p = 0.004,
Mann-Whitney U test), similar in non metastasizing and
metastasizing malignancies, and significantly higher in
MEC than ACC or PLGA (p < 0.0001, Kruskal-Wallis with
Dunn's post-hoc test), as show in Figure 3. Intensity of
staining was also much stronger in MEC.
For each histological type, positivity was almost restricted
to metastasizing ACC (in three out of ten cases; only one
non-metastasizing case depicted very few positive blood
vessels) and non-metastasizing PLGA (in eight out of sev-
enteen cases), while discretely increased IMD was
observed for metastasizing MEC compared to non-metas-
tasizing cases (Table 2). Representative images of CD105
positivity according to metastatic behavior of the lesions
is presented in Figure 4. For the very few PA with CD105
positive vessels, it was rare, of weak intensity, and only
focally observed in apparent fibrous septa. For ACC, pos-
itivity was of weak to moderate intensity, and it was
mostly observed surrounding tumoral nests. For PLGA,
CD105 positivity was predominantly weak to moderate,
and it was mostly found at the periphery of the lesions,
but eventually permeating tumoral parenchyma. Only for
MEC, strongly CD105 positive vessels were observed in
most of the lesions, permeating through or surrounding
tumoral nests.
Discussion
Metastasis is an important cause of death for patients with
cancer and there is evidence pointing out for a role of ang-
iogenesis in the dissemination of malignant tumors [15].
In an effort to investigate possible association between
formation of new blood vessels and development of
metastasis in salivary gland tumors, the present work
investigated the most frequent of these lesions (PA) as a
conceptual standard for non-metastasizing disease, as
well as three of the most important malignant neoplasms
for which metastasis is possible, but less (PLGA) or more
(ACC, MEC) frequent [16,17]. These lesions also diverge
regarding to differentiation and myoepithelial content
[18]. Another considerably common salivary gland can-
cer, adenocarcinoma NOS, was not included because of
the prominent and characteristic morphologic and behav-
ioral heterogeneities of this group of lesions. Work cover-
ing prognosis and new insights into biology of this rare
lesion has been recently released [19]. Other aggressive
tumors were not included because of its rarity and, in spite
of one of the largest number of primary samples in the lit-
erature, it was not possible to obtain a representative sam-
Table 1: Clinical and demographic data
Sex Age
Class or type of tumor (male:female) (years, mean ± SD)
Benign (pleomorphic adenoma) 1:1.5 52.0 ± 13.8
Malignant 1:1.5 50.3 ± 17.1
Malignant, non-metastasizing 1:1.9 49.6 ± 17
Malignant, metastasizing 1:0.4 54.5 ± 17.6
Adenoid cystic carcinoma 1:1.8 51.2 ± 16.6
Polymorphous low-grade adenocarcinoma 1:1.1 61.1 ± 13.3
Mucoepidermoid carcinoma 1:1.5 44.8 ± 17.9
Distribution of metastasizing tumors, according to histologi- cal type and site of metastatic implants Figure 1
Distribution of metastasizing tumors, according to 
histological type and site of metastatic implants.BMC Cancer 2009, 9:391 http://www.biomedcentral.com/1471-2407/9/391
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ple of metastatic implants because many were only
detected by imaging exams in organs such as lungs, bones,
liver, or brain. In addition, interpretation of the present
data is limited by the acknowledgement that an overall
five years follow-up time is too short to fully assess meta-
static behavior for ACC, since late distant manifestations
is a prominent finding in this disease [13,17,18].
CD105 expression has been demonstrated almost exclu-
sively in venous and arterial vessels surrounding and per-
meating tumors [10]. It also has been detected in non-
neoplastic tissues with increased angiogenic activity, such
as embryonic development and wound healing [2,4].
Greater accuracy (mainly specificity) of CD105 in demon-
strating new blood vessels compared with other mole-
cules such as CD34 and factor VIII is clear in the literature
[20-22]. As expected, in the present work CD105-positive
vessels were absent in normal salivary gland. Even almost
half of the tumors did not present such finding, corrobo-
rating the specificity of CD105 in demonstrating newly
formed blood vessels, but it also evidences that neoplastic
development does not always require prominent angio-
genesis. Costa et al. [23] observed discrepancy between
proliferation of salivary gland tumor cells and closeness to
vessels stained by CD34, suggesting that possibly tumors
such as ACC maintain metabolic activity via an oxygen-
independent process. Anyway, there was a noticeable
Frequency of cases with positive staining for CD105, according to: A. biological behavior; and B. histological type Figure 2
Frequency of cases with positive staining for CD105, according to: A. biological behavior; and B. histological 
type.
Intratumoral microvessel density (IMD), evaluated by CD105  staining, according to biological behavior and histological type Figure 3
Intratumoral microvessel density (IMD), evaluated 
by CD105 staining, according to biological behavior 
and histological type.BMC Cancer 2009, 9:391 http://www.biomedcentral.com/1471-2407/9/391
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increase in the mean IMD from benign to malignant
lesions, therefore indicating that vascularization contrib-
utes to or reflects aggressiveness in salivary gland tumors.
Increased demand for blood supply because of accelerated
growth or acquired ability of tumor cells to produce ang-
iogenic factors could explain this finding [2].
In the present work, mean IMD assessed by CD105 was
not significantly different between the entire samples of
malignant tumors that did or not metastasized, and even
all of the PLGA and more than half of the ACC that metas-
tasized did not present CD105 positive vessels, suggesting
that angiogenesis is neither an absolute determinant nor
required for acquisition of metastatic phenotype in these
salivary gland tumors. However, only metastasizing ACC
and all of metastasizing MEC were positive for CD105,
suggesting that angiogenesis would be a priming step for
at least some of these lesions to disseminate, specially for
ACC. Zhang and Peng [24] observed that ACC cell line-
ages with higher invasive and metastatic potential were
also more efficient than other with low metastatic behav-
ior in promoting migration and tube formation of
endothelial cells in vitro.
Another interesting finding of the present work was the
continuous increase of IMD from ACC to PLGA and then
to MEC. It is not apparently correlated to the aggressive-
ness of these lesions, but their myoepithelial content may
help to explain such difference. There is evidence that
myoepithelial cells inhibit angiogenesis [25,26]. It could
greatly impair angiogenesis in PA and ACC. This effect
would be only partial in PLGA, where myoepithelial con-
tent is intermediate between ACC and MEC. The latter
does not present myoepithelial differentiation, and there-
fore would not present their inhibitory effect. Similarly to
the present results, Costa et al. [23] observed less frequent
staining of vessels by CD105 in ACC than MEC. In addi-
tion, these authors observed almost identical mean IMD
in non-metastasizing and metastasizing ACC, in the same
Table 2: CD105 immunohistochemical localization in primary salivary gland tumors (IMD = intratumoral microvessel density) [14].
CD105 positivity
Type and metastatic status N Frequency IMD (mean ± SD)
Adenoid cystic carcinoma
Primary, non-metastasizing 41 2.4% 0
Primary, metastasizing 10 30.0% 0.7 (± 1.3)
Polymorphous low-grade adenocarcinoma
Primary, non-metastasizing 17 47.1% 1.6 (± 2.0)
Primary, metastasizing 2 0 0
Mucoepidermoid carcinoma
Primary, non-metastasizing 36 83.3% 4.8 (± 6.0)
Primary, metastasizing 4 100% 6.2 (± 2.1)
Immunohistochemical staining of CD105 in salivary gland  tumors (streptavidin-biotin-peroxidase technique, original  magnification = × 250) Figure 4
Immunohistochemical staining of CD105 in salivary 
gland tumors (streptavidin-biotin-peroxidase tech-
nique, original magnification = × 250). A. Pleomorphic 
adenoma, depicting very weak staining (arrow). B. Only one 
primary non metastasizing adenoid cystic carcinoma was pos-
itive for CD105 staining, of weak intensity (arrow). C. Ade-
noid cystic carcinoma, primary metastasizing lesion, depicting 
clear and strong positivity around and within tumoral nests 
(arrows). D. Polymorphous low-grade adenocarcinoma, pri-
mary non-metastasizing lesion, with strongly positive vessels 
(arrow) permeating tumoral strands. E. Mucoepidermoid car-
cinoma, primary non-metastasizing lesion, with strongly posi-
tive vessels (arrows) around tumoral nests. F. 
Mucoepidermoid carcinoma, primary metastasizing lesion, 
evidencing numerous and strongly positive vessels (arrows) 
intermingling tumoral parenchima.BMC Cancer 2009, 9:391 http://www.biomedcentral.com/1471-2407/9/391
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way of the present work, but did not evaluate PLGA or
metastasizing MEC.
Conclusion
The results of the present work contribute to the knowl-
edge on the biology of salivary gland tumors, since
increased angiogenesis was observed in malignant
tumors. Further, it was also higher in MEC than in PLGA
and particularly than in ACC and PA, supporting a likely
role of myoepithelial cells as regulators of the formation
of new blood vessels. Diagnostic implications are also
present, since those ACC with CD105 positive vessels
seems to be at increased risk for metastasis.
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